Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
March 14 2022 - 7:00AM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage
company advancing an integrated and sustainable pipeline of genetic
therapies for rare childhood disorders, today announces the
appointment of Fady Malik, M.D., Ph.D., to its Board of Directors.
Dr. Malik brings nearly 25 years of experience as an
internationally recognized cardiovascular physician-scientist and
highly successful biopharmaceutical executive. He will serve as an
independent non-executive director.
“Fady is a tremendous addition to our Board of Directors,
especially at this exciting time as we seek agency alignment on a
Phase 2, potentially registration-enabling clinical study for Danon
Disease, and continue to build and expand our Wave 2 pipeline,”
said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma.
“Fady’s deep understanding of R&D with a focus on cardiology,
hands on experience building and growing a biotech company and
success bringing a medicine from the bench to patients, especially
in cardiology, will be incredibly valuable as we work to deliver
our world-class pipeline to patients with rare diseases such as
Danon. I am thrilled to welcome Fady to the board and look forward
to his valuable perspective and experience.”
Dr. Malik is Executive Vice President of Research and
Development at Cytokinetics, a late-stage biopharmaceutical
company, where he has worked in a variety of positions since he
joined the founders to launch the company. At Cytokinetics, Dr.
Malik has led R&D efforts resulting in multiple Investigational
New Drug submissions, advancement of four programs to Phase 3, and
the submission of the company’s first New Drug Application. Dr.
Malik is also a Clinical Professor of Medicine in the Cardiology
Division of the University of California, San Francisco, where he
has held an appointment since 2000. Until 2019, he was a practicing
Interventional Cardiologist at the San Francisco Veterans
Administration Medical Center for over 18 years.
“I am thrilled to join Rocket’s Board of Directors to work with
the passionate and motivated leaders of this pioneering company
seeking to advance the field of gene therapy as it might benefit
patients,” said Dr. Malik. “I am particularly impressed with the
Company’s robust and deep pipeline of clinical-stage programs in
conditions of high unmet medical need, most lacking alternative
treatments. I hope to contribute to Rocket’s goal of bringing these
treatments to patients as quickly as possible.”
Dr. Malik is an inventor on more than 20 issued patents and has
authored or co-authored over 60 publications appearing in prominent
peer-reviewed journals. He received a B.S. from the University of
California, Berkeley and a Ph.D. and M.D. from the University of
California, San Francisco.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of genetic therapies that
correct the root cause of complex and rare childhood disorders. The
Company’s platform-agnostic approach enables it to design the best
therapy for each indication, creating potentially transformative
options for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LVV)-based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections which are frequently fatal, and Pyruvate Kinase
Deficiency (PKD), a rare, monogenic red blood cell disorder
resulting in increased red cell destruction and mild to
life-threatening anemia. Rocket’s first clinical program using
adeno-associated virus (AAV)-based gene therapy is for Danon
Disease, a devastating, pediatric heart failure condition. For more
information about Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding its guidance for 2022 in light of
COVID-19, the safety and effectiveness of product candidates that
Rocket is developing to treat Fanconi Anemia (FA), Leukocyte
Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),
and Danon Disease, the expected timing and data readouts of
Rocket’s ongoing and planned clinical trials, Rocket’s plans for
the advancement of its Danon Disease program following the lifting
of the FDA’s clinical hold and the safety, effectiveness and timing
of related pre-clinical studies and clinical trials, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to
substantial risks, uncertainties and assumptions. You should not
place reliance on these forward-looking statements, which often
include words such as "believe," "expect," "anticipate," "intend,"
"plan," "will give," "estimate," "seek," "will," "may," "suggest"
or similar terms, variations of such terms or the negative of those
terms. Although Rocket believes that the expectations reflected in
the forward-looking statements are reasonable, Rocket cannot
guarantee such outcomes. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including, without limitation, Rocket’s
ability to monitor the impact of COVID-19 on its business
operations and take steps to ensure the safety of patients,
families and employees, the interest from patients and families for
participation in each of Rocket’s ongoing trials, our expectations
regarding the delays and impact of COVID-19 on clinical sites,
patient enrollment, trial timelines and data readouts, our
expectations regarding our drug supply for our ongoing and
anticipated trials, actions of regulatory agencies, which may
affect the initiation, timing and progress of pre-clinical studies
and clinical trials of its product candidates, Rocket’s dependence
on third parties for development, manufacture, marketing, sales and
distribution of product candidates, the outcome of litigation, and
unexpected expenditures, as well as those risks more fully
discussed in the section entitled "Risk Factors" in Rocket’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2021, filed November 5, 2021 with the SEC. Accordingly, you should
not place undue reliance on these forward-looking statements. All
such statements speak only as of the date made, and Rocket
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220314005237/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com
Investors Jessie Yeung, M.B.A. Vice President, Investor
Relations and Corporate Finance investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Sep 2023 to Sep 2024